Skip to main content
. 2020 Aug 4;11:527. doi: 10.3389/fendo.2020.00527

Table 1.

Patient characteristics at the time of diagnosis and treatment.

Total subjects (n = 25) Microadenoma (n = 11) (44%) Macroadenoma (n = 14) (56%) P-value*
Follow-up period (yr) 3.0 (2.0, 4.1)
Gender (female) 20/25 (80%) 11 (55%) 9 (45%) 0.134
Age at diagnosis (median, IQR) (yr) 16.9 (16.3, 18.0) (range: 10.9–18.4) 17.1 (16.7, 17.7) 16.8 (14.3, 18.1) 0.727
Height (SDS) 0.3 (−1.2, 0.7) 0.3 (−0.6, 1.7) −1.6 (0.1, 0.7) 0.501
BMI (SDS) 0.4 (−0.2, 0.8) 0.3 (0.1, 0.4) 0.5 (−0.2, 1.3) 0.434
PRL at diagnosis (ng/mL) 207.0 (116.6, 1056.5) 114.2 (85.6, 189.5) 516.0 (202.8, 3567.5) <0.001
Maximum tumor diameter (mm) 12.0 (9.0, 21.5) (range: 4–74) 9 (7, 10) 21 (14.3, 26.3) <0.001
Panhypopituitarism 11/25 (44%) 1/11 (9%) 10/14 (71%) 0.008
Operation (TSA) 15/25 (60%) 3/11 (27%) 12/14 (86%) 0.003
Immediate postoperative PRL levels 25.0 (2.9, 83.0) 2.7 (1.3, 2.9) 31.7 (1.2, 1,102) 0.031
Nadir PRL level (ng/mL) 9.4 (2.6, 34.5) 7.5 (0.6, 33.0) 9.7 (4.9, 43.3) 0.373
Ki-67 index 3.1 (2.0, 5.0) 3 (0.1, 5) 3.4 (1.2, 16.0) 0.536
Responsiveness to DAs 10/18 (56%) 5/7 (71%) 5/11 (45%) 0.436
At age of first use with CAB (yr) 17.5 (16.3, 19.6) 18.4 (17.2, 19.6) 16.6 (13.5, 19.5) 0.228
CAB peak (mg/wk) 1.5 (1.0, 2.0) 1.0 (1.0, 1.9) 2.0 (1.1, 2.4) 0.130
CAB duration (yr) 1.1 (0.1, 2.2) 0.3 (0.1, 1.1) 1.8 (0.4, 2.7) 0.081
BRC peak (mg/day) 30 (3.4, 105.0) 7.5 52.5 (3.1, 140) 1.000
BRC duration (yr) 1.9 (1.1, 7.6) 0.9 2.1 (1.4, 8.2) 0.333

Data are expressed as median (IQR) or mean ± sd.

BMI, body mass index; IQR, interquartile range; SD, standard deviation; PRL, prolactin; TSA, transphenoidal approach; DAs, dopamine agonists; CAB, cabergoline; BRC, bromocriptine.

*

Significant association was classified as P < 0.05.

Reference range of serum prolactin: 72–10,000 ng/mL.